Immunotherapy and fatigue: what we know and what we don’t know
Open Access
- 13 April 2021
- journal article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 12 (8), 719-720
- https://doi.org/10.18632/oncotarget.27946
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Associations between the gut microbiome and fatigue in cancer patientsScientific Reports, 2021
- Testosterone deficiency in men receiving immunotherapy for malignant melanomaOncotarget, 2021
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline SummaryJournal of Oncology Practice, 2018
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeThe New England Journal of Medicine, 2018
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Cancer-related fatigue—mechanisms, risk factors, and treatmentsNature Reviews Clinical Oncology, 2014
- Inflammation and cancer-related fatigue: Mechanisms, contributing factors, and treatment implicationsBrain, Behavior, and Immunity, 2012
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010